Related references
Note: Only part of the references are listed.Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2020
DIABETES CARE (2020)
Efficacy and safety of an expanded dulaglutide dose range: A phase 2, placebo-controlled trial in patients with type 2 diabetes using metformin
Juan P. Frias et al.
DIABETES OBESITY & METABOLISM (2019)
Incorporating and interpreting regulatory guidance on estimands in diabetes clinical trials: The PIONEER 1 randomized clinical trial as an example
Vanita R. Aroda et al.
DIABETES OBESITY & METABOLISM (2019)
Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials
Soren L. Kristensen et al.
LANCET DIABETES & ENDOCRINOLOGY (2019)
Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial
Richard E. Pratley et al.
LANCET DIABETES & ENDOCRINOLOGY (2018)
Treatment Intensification in Type 2 Diabetes: A Real-World Study of 2-OAD Regimens, GLP-1 RAs, or Basal Insulin
Lawrence Blonde et al.
DIABETES THERAPY (2018)
Treatment Intensification in Type 2 Diabetes: A Real-World Study of 2-OAD Regimens, GLP-1 RAs, or Basal Insulin
Lawrence Blonde et al.
DIABETES THERAPY (2018)
Efficacy and safety profile of once-weekly dulaglutide in type 2 diabetes: a report on the emerging new data
Anne J. Kugler et al.
DIABETES METABOLIC SYNDROME AND OBESITY-TARGETS AND THERAPY (2018)
Glucose Concentrations of Less Than 3.0 mmol/L (54 mg/dL) Should Be Reported in Clinical Trials: A Joint Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes
Stephanie A. Amiel et al.
DIABETES CARE (2017)
Assessment of Pancreas Safety in the Development Program of Once-Weekly GLP-1 Receptor Agonist Dulaglutide
Michael A. Nauck et al.
DIABETES CARE (2017)
Clinical Pharmacokinetics of Dulaglutide in Patients with Type 2 Diabetes: Analyses of Data from Clinical Trials
Jeanne S. Geiser et al.
CLINICAL PHARMACOKINETICS (2016)
A Phase 2, Randomized, Dose-Finding Study of the Novel Once-Weekly Human GLP-1 Analog, Semaglutide, Compared With Placebo and Open-Label Liraglutide in Patients With Type 2 Diabetes
Michael A. Nauck et al.
DIABETES CARE (2016)
Efficacy and safety of dulaglutide in the treatment of type 2 diabetes: a comprehensive review of the dulaglutide clinical data focusing on the AWARD phase 3 clinical trial program
Johan Jendle et al.
DIABETES-METABOLISM RESEARCH AND REVIEWS (2016)
Dose-finding results in an adaptive, seamless, randomized trial of once-weekly dulaglutide combined with metformin in type 2 diabetes patients (AWARD-5)
Z. Skrivanek et al.
DIABETES OBESITY & METABOLISM (2014)
Pancreatic Safety of Incretin-Based Drugs - FDA and EMA Assessment
Amy G. Egan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Hypoglycemia and Diabetes: A Report of a Workgroup of the American Diabetes Association and The Endocrine Society
Elizabeth R. Seaquist et al.
DIABETES CARE (2013)
Graphical approaches for multiple comparison procedures using weighted Bonferroni, Simes, or parametric tests
Frank Bretz et al.
BIOMETRICAL JOURNAL (2011)
Share Paper
